|
KR20210006356A
(ko)
|
2018-04-04 |
2021-01-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
|
CN114867726B
(zh)
|
2019-10-28 |
2023-11-28 |
默沙东有限责任公司 |
Kras g12c突变体的小分子抑制剂
|
|
US12479834B2
(en)
|
2019-11-29 |
2025-11-25 |
Taiho Pharmaceutical Co., Ltd. |
Phenol compound or salt thereof
|
|
TW202400170A
(zh)
|
2022-05-19 |
2024-01-01 |
美商建南德克公司 |
氮雜－四環氧氮呯化合物及其用途
|
|
MA71388A
(fr)
*
|
2022-07-05 |
2025-04-30 |
Pfizer Inc. |
Composés pyrido[4,3-d]pyrimidines
|
|
WO2024015262A1
(en)
*
|
2022-07-09 |
2024-01-18 |
Blossomhill Therapeutics, Inc. |
Fused ring kras inhibitors for treating disease
|
|
CA3261681A1
(en)
|
2022-08-05 |
2024-02-08 |
Kumquat Biosciences Inc. |
HETEROCYCLIC COMPOUNDS AND THEIR USES
|
|
WO2024032703A1
(en)
*
|
2022-08-11 |
2024-02-15 |
Beigene, Ltd. |
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
|
|
TW202408512A
(zh)
*
|
2022-08-12 |
2024-03-01 |
大陸商正大天晴藥業集團股份有限公司 |
三環類化合物及其醫藥用途
|
|
WO2024041573A1
(en)
*
|
2022-08-25 |
2024-02-29 |
Zai Lab (Shanghai) Co., Ltd. |
Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
|
|
WO2024112654A1
(en)
|
2022-11-21 |
2024-05-30 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
KR20250120376A
(ko)
*
|
2022-12-07 |
2025-08-08 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
축합환 화합물 및 이의 응용
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|
|
WO2024178304A1
(en)
*
|
2023-02-24 |
2024-08-29 |
Alterome Therapeutics, Inc. |
Kras modulators
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024209339A1
(en)
|
2023-04-05 |
2024-10-10 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
WO2024208305A1
(zh)
*
|
2023-04-07 |
2024-10-10 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
WO2024213979A1
(en)
*
|
2023-04-10 |
2024-10-17 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
CN120882725A
(zh)
*
|
2023-04-11 |
2025-10-31 |
吉利德科学公司 |
Kras调节化合物
|
|
WO2024218686A1
(en)
*
|
2023-04-20 |
2024-10-24 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
EP4713330A1
(en)
*
|
2023-05-16 |
2026-03-25 |
HUTCHMED Limited |
Tricyclic compounds and uses thereof
|
|
WO2025006783A2
(en)
*
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
AU2024323424A1
(en)
|
2023-08-17 |
2026-03-05 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025049619A1
(en)
|
2023-08-29 |
2025-03-06 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025085748A1
(en)
*
|
2023-10-20 |
2025-04-24 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
CN117700374A
(zh)
*
|
2023-12-25 |
2024-03-15 |
吉尔多肽生物制药(大连市)有限公司 |
手性高吗啉-3-甲酸的制备方法
|
|
WO2025148868A1
(zh)
*
|
2024-01-08 |
2025-07-17 |
泰励生物科技（上海）有限公司 |
一种抗体偶联药物及其用途
|
|
WO2025168072A1
(en)
*
|
2024-02-08 |
2025-08-14 |
Beigene (Suzhou) Co., Ltd. |
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
WO2026035947A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|